These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 16734214)

  • 1. [High risk prostate cancer results of one year RT-HT].
    Delaporte V; Muracciole X; Lechevalier E; Bastide C; Cowen D; Rossi D; Coulange C
    Prog Urol; 2005 Dec; 15(6 Suppl 1):1256-61. PubMed ID: 16734214
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prostate cancer at high risk of recurrence: results of 12 months of radiotherapy-hormone therapy].
    Delaporte V; Muracciole X; Lechevallier E; Bastide C; Cowen D; Rossi D; Coulange C
    Prog Urol; 2005 Apr; 15(2):260-4. PubMed ID: 15999604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
    Chen RC; Sadetsky N; Chen MH; Carroll PR; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):36-9. PubMed ID: 19233568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer.
    Heymann JJ; Benson MC; O'Toole KM; Malyszko B; Brody R; Vecchio D; Schiff PB; Mansukhani MM; Ennis RD
    J Clin Oncol; 2007 Jan; 25(1):77-84. PubMed ID: 17194907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combined radiotherapy and hormone therapy in non-metastatic adenocarcinoma of prostate].
    Lopez S; Simon JM; Mazeron JJ
    Bull Cancer; 2009 Mar; 96(3):261-70. PubMed ID: 19318304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk-based management of prostate cancer.
    D'Amico AV
    N Engl J Med; 2011 Jul; 365(2):169-71. PubMed ID: 21751910
    [No Abstract]   [Full Text] [Related]  

  • 7. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Definitive conformal radiotherapy for localized high-risk prostate cancer: a long-term follow-up study with PSA course.
    Bruns F; Franzki C; Wegener G; Karstens JH
    Anticancer Res; 2007; 27(4A):1847-51. PubMed ID: 17649783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease.
    D'Amico AV; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; Chen MH
    J Clin Oncol; 2009 Aug; 27(24):3923-8. PubMed ID: 19597029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
    Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T;
    Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does hormone therapy exacerbate the adverse effects of radiotherapy in men with prostate cancer? A quality of life study.
    Grant JD; Litwin MS; Kwan L; Lee SP; Steinberg ML; King CR
    J Urol; 2011 May; 185(5):1674-80. PubMed ID: 21419449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure to achieve a PSA level Mitchell DM; McAleese J; Park RM; Stewart DP; Stranex S; Eakin RL; Houston RF; O'Sullivan JM
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1467-71. PubMed ID: 17689886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study.
    Graff JN; Mori M; Li H; Garzotto M; Penson D; Potosky AL; Beer TM
    J Urol; 2007 Apr; 177(4):1307-12. PubMed ID: 17382720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy?
    Pai HH; Eldridge B; Bishop D; Alexander A; Lesperance M; Blood P; Lim J; Ludgate C
    Can J Urol; 2009 Apr; 16(2):4541-52. PubMed ID: 19364426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Real-time tumor-tracking radiotherapy combined with neoadjuvant hormonal therapy for prostate cancer].
    Kitamura K; Shirato H; Shimizu S; Miyasaka K; Demura T; Shinohara N; Harabayashi T
    Nihon Rinsho; 2000 Jul; 58 Suppl():326-9. PubMed ID: 11022742
    [No Abstract]   [Full Text] [Related]  

  • 17. Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?
    Pollack A; Horwitz EM
    Nat Clin Pract Oncol; 2005 Jan; 2(1):12-3. PubMed ID: 16264846
    [No Abstract]   [Full Text] [Related]  

  • 18. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
    Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?
    Miyamoto H; Messing EM; Chang C
    Nat Clin Pract Oncol; 2005 May; 2(5):236-7. PubMed ID: 16264955
    [No Abstract]   [Full Text] [Related]  

  • 20. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy.
    D'Amico AV; Renshaw AA; Loffredo B; Chen MH
    Cancer; 2007 Oct; 110(8):1723-8. PubMed ID: 17828774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.